Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocimum sanctum leaf extract, derived from the Holy Basil or Tulsi plant, is a botanical preparation rich in bioactive phytochemicals such as eugenol, caryophyllene, and ursolic acid. It is widely recognized in Ayurvedic medicine for its adaptogenic, anti-inflammatory, and antioxidant properties. The extract is primarily investigated for its ability to mitigate oxidative stress and inflammation by scavenging free radicals and enhancing the activity of endogenous antioxidant enzymes. In preclinical models of Chronic Obstructive Pulmonary Disease (COPD), it has demonstrated the potential to reduce lung injury and inflammation induced by cigarette smoke by upregulating enzymes like superoxide dismutase (SOD) and catalase. While commonly used as a dietary supplement for stress and general wellness, it is under exploration as a therapeutic option for inflammatory and respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ocimum sanctum leaf extract.